Top Cancer Centers; Phase III Win in Prostate Cancer; Screening Recs for Anal Cancer

U.S. News & World Report released its annual ranking of top cancer centers.

Darolutamide (Nubeqa) plus androgen deprivation therapy (ADT) improved radiologic progression-free survival over ADT alone in metastatic hormone-sensitive prostate cancer in the ARANOTE trial, meeting the phase III study’s primary endpoint, Bayer announced.

Meanwhile, results of the phase III TiNivo-2 trial in advanced metastatic renal cell carcinoma showed that post-immunotherapy treatment with nivolumab (Opdivo) and a low dose of tivozanib (Fotivda) failed to improve progression-free survival versus a standard dose of tivozanib alone, AVEO Oncology announced.

Hydroxyurea had no effect on ovarian reserve for girls and young women living with sickle cell disease, a study showed, suggesting that fertility preservation measures prior to treatment may be unnecessary. (Blood Advances)

Use of cyclophosphamide-based graft-versus-host disease prophylaxis after an allogeneic hematopoietic cell transplant attenuated the disparity in outcomes between matched and mismatched unrelated donors. (Journal of Clinical Oncology)

A population-based study suggests the socioeconomic status of cell donors affects the health outcomes of blood cancer patients who undergo hematopoietic cell transplantation. (PNAS)

Women are more likely to die from breast and cervical cancers in a cluster of southeastern states where preventive care lags behind the rest of the country, according to a Commonwealth Fund analysis.

New federal guidelines for people with HIV recommend high resolution anoscopy as part of an anal cancer screening program to help detect and treat precancers. (National Institutes of Health)

Current screening protocols fail to catch some people who carry genetic mutations associated with Lynch syndrome and hereditary breast and ovarian cancer syndrome. (JCO Precision Oncology)

Neha Vapiwala, MD, of the University of Pennsylvania in Philadelphia, was voted president-elect of the American Society for Radiation Oncology.

The FDA is advising against an accelerated approval pathway for the investigational immunotherapy combination of botensilimab and balstilimab for relapsed/refractory microsatellite stable colorectal cancer, said drugmaker Agenus.

A 29-year-old Ohio man has filed a lawsuit accusing two dozen companies of contaminating his water supply with fluorochemicals and causing his testicular cancer. (Newsweek)

Please enable JavaScript to view the

comments powered by Disqus.